BlackRock
KYTX icon

BlackRock’s Kyverna Therapeutics KYTX Stock Holding History

BlackRock’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.57M Buy
877,078
+332,539
+61% +$2.77M ﹤0.01% 3659
2025
Q4 		$5.12M Buy
544,539
+62,485
+13% +$464K ﹤0.01% 3831
2025
Q3 		$2.89M Sell
482,054
-51,413
-10% -$206K ﹤0.01% 3981
2025
Q2 		$1.64M Sell
533,467
-1,142,801
-68% -$2.83M ﹤0.01% 4120
2025
Q1 		$3.24M Buy
1,676,268
+3,775
+0.2% +$11.2K ﹤0.01% 3814
2024
Q4 		$6.26M Buy
1,672,493
+152,232
+10% +$729K ﹤0.01% 3636
2024
Q3 		$7.43M Buy
1,520,261
+66,594
+5% +$513K ﹤0.01% 3555
2024
Q2 		$10.9M Buy
1,453,667
+703,701
+94% +$10.8M ﹤0.01% 3342
2024
Q1 		$18.6M Buy
+749,966
New +$20.9M ﹤0.01% 3030

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

BlackRock's KYTX Position: Q1 2026 in Review

BlackRock increased its Kyverna Therapeutics (KYTX) stake by 61% in Q1 2026, buying an estimated $2.77M and bringing the position to 877,078 shares worth $7.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3659.

BlackRock first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $18.6M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • BlackRock held 877,078 shares of Kyverna Therapeutics worth $7.57M as of Q1 2026.
  • BlackRock bought 332,539 Kyverna Therapeutics shares in Q1 2026, an estimated $2.77M.
  • Kyverna Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3659 holding.
  • BlackRock first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • BlackRock's Kyverna Therapeutics position peaked at $18.6M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.